abstract |
(57) [Summary]nFor promotion of an HIV-1 specific immune response (eg, promotion of HIV-1 specific T cells) in adult and pediatric patients with HIV-1 infection, and patients co-infected with HIV-1 and HVC Discloses the use of interferon α (eg, pegylated interferon α-2a or pegylated interferon α-2b) for the preparation of a medicament, wherein the medicament comprises a therapeutically effective amount of pegylated interferon α (eg, pegylated interferon α). Interferon α-b2). |